Cargando…
Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice
Cancer gene panels (CGPs) are already used in clinical practice to match tumor's genetic profile with available targeted therapies. We aimed to determine if CGPs could also be applied to estimate tumor mutational load and predict clinical benefit to PD-1 and CTLA-4 checkpoint blockade therapy....
Autores principales: | Campesato, Luís Felipe, Barroso-Sousa, Romualdo, Jimenez, Leandro, Correa, Bruna R., Sabbaga, Jorge, Hoff, Paulo M., Reis, Luiz F. L., Galante, Pedro Alexandre F., Camargo, Anamaria A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741447/ https://www.ncbi.nlm.nih.gov/pubmed/26439694 |
Ejemplares similares
-
Acute Acalculous Cholecystitis in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib
por: da Fonseca, Leonardo Gomes, et al.
Publicado: (2014) -
High IL-1R8 expression in breast tumors promotes tumor growth and contributes to impaired antitumor immunity
por: Campesato, Luis Felipe, et al.
Publicado: (2017) -
PD-1(T) TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
por: Hummelink, Karlijn, et al.
Publicado: (2022) -
PD-1 inhibitors in endometrial cancer
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2017) -
NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
por: Yan, Sen, et al.
Publicado: (2022)